Outsourcing

Feliza Mirasol is the science editor for 

Articles

The annual survey predicts that four of the five biggest biologics capacity holders in 2028 will comprise CMOs, which will control 45% of all CMO capacity in Asia.

CPHI Annual Survey Suggests 54% of Biologics Capacity in 2028 to be Held by CMOs and Hybrid Companies

Cellevate's nanofiber microcarriers are the first on the market for use in  manufacturing viral vectors used in gene therapy production, according to the company.

Cellevate to Pre-Launch Nanofiber Microcarriers for Viral Vector Production at CPHI Milan

SGD Pharma plans to showcase its siliconized molded glass vials at CPHI Milan as part of its range of sustainable products and services.

SGD Pharma to Showcase Sustainable Packaging with Siliconized Molded Glass Vials at CPHI Milan

Under the long-term supply agreement, Lonza will manufacture CASGEVY (exagamglogene autotemcel) for Vertex at its facility in Geleen, the Netherlands, and plans to expand manufacturing to Portsmouth, NH, in the United States.

Lonza to Manufacture Commercial Supply of Vertex’s Sickle Cell Disease Gene-Edited Cell Therapy, CASGEVY

Rentschler Biopharma now offers a new lentiviral vector manufacturing toolbox at its site in Stevenage, UK.

Rentschler Biopharma Launches New LV Vector Manufacturing Toolbox

Editor of Pharmaceutical Technology Europe

As the field of bioanalytical testing evolves, it is important for drug developers to stay at the forefront of the advancements to ensure they remain competitive.

Leveraging Bioanalytical Studies Advancements

Chris Spivey is the editorial director of 

Videos

Christian Cobaugh, CEO and founder of Vernal Biosciences, considers the outsourcing landscape for mRNA production.

A Look at the Outsourcing Landscape for mRNA (BIO 2024)

Pluri’s newly launched CDMO business will manufacture two novel cell therapy product candidates for Kadimastem.

Pluri’s CDMO Business to Manufacture Cell Therapy Candidates from Kadimastem

Under this partnership, AGC Biologics and BioConnection will provide development and manufacturing capabilities for biopharmaceutical drug substance and drug product. 

AGC Biologics and BioConnection Team Up on Biopharma Drug Development and Manufacturing

The Mirus Bio acquisition will boost Merck KGaA’s viral vector manufacturing services. 

Contract Manufacturing, Biopharmaceutical Production